A review of existing research published in the Journal of the Endocrine Society suggests that Alzheimer's disease and dementia may be more common in women with polyendocrine metabolic ovarian syndrome (PMOS), the condition formerly known as polycystic ovary syndrome (PCOS). The authors pulled together prior work through a comprehensive PubMed search running from the database's inception through October 2025.
PMOS affects an estimated 10% to 15% of women worldwide and is tied to a broad set of health problems, including diabetes, heart disease, stroke, depression, anxiety, infertility and endometrial cancer. The condition can have lifelong effects, and the source notes it can also affect males, though in different ways.
Clinically, women with PMOS show mild but reproducible problems with executive function and memory, along with structural and functional changes in the brain. The review's authors read these patterns as a possible sign of greater risk for Alzheimer's and dementia.
The more specific conclusion is that the link appears to run mainly through metabolic conditions that often accompany PMOS, particularly insulin resistance and obesity, rather than through PMOS acting on its own. That distinction matters because it points researchers toward metabolic health as a possible route by which the risk builds, which could shape which biological pathways get studied next.
The authors also say the review highlights important gaps in knowledge and identifies key areas for future research. Lead author Richard Azziz framed the work as a chance to find what these two conditions share, with the aim of uncovering new pathways and causes that could guide novel treatments.